Extended safety and efficacy studies of the attenuated Brucella vaccine candidates 16MΔvjbR and S19ΔvjbR in the immunocompromised IRF-1 -/- mouse model

Clinical and Vaccine Immunology

Volumn 19, Issue 2, 2012, Pages 249-260

  Arenas Gamboa, A M ^a,b   Rice Ficht, A C ^a,b   Fan, Y ^a,b   Kahl McDonagh, M M ^a   Ficht, T A ^a  

^a TEXAS A AND M UNIVERSITY   (United States)

^b TEXAS A M COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRUCELLA VACCINE; INTERFERON REGULATORY FACTOR 1; LIVE VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL COLONIZATION; BODY TEMPERATURE; BRUCELLA ABORTUS; BRUCELLA MELITENSIS; BRUCELLOSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EXPERIMENTAL INFECTION; FEMALE; GENE DELETION; GRANULOMATOUS INFLAMMATION; HISTOPATHOLOGY; HYPOTHERMIA; IMMUNOCOMPETENCE; INFLAMMATION; KNOCKOUT MOUSE; LIVER; MOUSE; NEUTROPHILIC INFLAMMATORY RESPONSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN; SURVIVAL; VACCINATION; VIRUS GENE; VJBR GENE;

ANIMALS; BRUCELLA; BRUCELLA VACCINE; BRUCELLOSIS; DISEASE MODELS, ANIMAL; FEMALE; INTERFERON REGULATORY FACTOR-1; MICE; MICE, KNOCKOUT; VACCINATION; VACCINES, ATTENUATED;

EID: 84856426056     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.05321-11     Document Type: Article

References (36)

1. Adone R, et al. 2005. Protective properties of rifampin-resistant rough mutants of Brucella melitensis. Infect. Immun. 73:4198-4204. (Pubitemid 40923162)
2. Arenas-Gamboa AM, Ficht TA, Kahl-McDonagh MM, Gomez G, Rice-Ficht AC. 2009. The Brucella abortus S19 deltavjbR live vaccine candidate is safer than S19 and confers protection against wild-type challenge in BALB/c mice when delivered in a sustained-release vehicle. Infect. Immun. 77:877-884.
3. Arenas-Gamboa AM, Ficht TA, Kahl-McDonagh MM, Rice-Ficht AC. 2008. Immunization with a single dose of a microencapsulated Brucella melitensis mutant enhances protection against wild-type challenge. Infect. Immun. 76:2448-2455.
4. Atwood RP, Kass EH. 1964. Relationship of body temperature to the lethal action of bacterial endotoxin. J. Clin. Invest. 43:151-169.
5. Clemmer TP, et al. 1992. Hypothermia in the sepsis syndrome and clinical outcome. The Methylprednisolone Severe Sepsis Study Group. Crit. Care Med. 20:1395-1401.
6. Delrue RM, et al. 2005. A quorum-sensing regulator controls expression of both the type IV secretion system and the flagellar apparatus of Brucella melitensis. Cell. Microbiol. 7:1151-1161.
7. Ficht TA, Kahl-McDonagh MM, Arenas-Gamboa AM, Rice-Ficht AC. 2009. Brucellosis: the case for live, attenuated vaccines. Vaccine 27(Suppl 4):D40-D43.
8. Grillo MJ, et al. 2006. Increases of efficacy as vaccine against Brucella abortus infection in mice by simultaneous inoculation with avirulent smooth bvrS/bvrR and rough wbkA mutants. Vaccine 24:2910-2916.
9. Guihot A, Bossi P, Bricaire F. 2004. Bioterrorism with brucellosis. Presse Med. 33:119-122. (In French.) (Pubitemid 38165898)
10. Honda K, Takaoka A, Taniguchi T. 2006. Type I interferon [corrected] gene induction by the interferon regulatory factor family of transcription factors. Immunity 25:349-360. (Pubitemid 44354220)
11. Honda K, Taniguchi T. 2006. IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat. Rev. Immunol. 6:644-658. (Pubitemid 44298214)
12. Kahl-McDonagh MM, et al. 2006. Evaluation of novel Brucella melitensis unmarked deletion mutants for safety and efficacy in the goat model of brucellosis. Vaccine 24:5169-5177. (Pubitemid 43818193)
13. Kahl-McDonagh MM, Ficht TA. 2006. Evaluation of protection afforded by Brucella abortus and Brucella melitensis unmarked deletion mutants exhibiting different rates of clearance in BALB/c mice. Infect. Immun. 74:4048-4057. (Pubitemid 43993337)
14. Kano S, et al. 2008. The contribution of transcription factor IRF1 to the interferon-gamma-interleukin 12 signaling axis and TH1 versus TH-17 differentiation of CD4+ T cells. Nat. Immunol. 9:34-41. (Pubitemid 350286201)
15. Klesius PH, Kramer TT, Swann AI, Christenberry CC. 1978. Cell-mediated immune response after Brucella abortus S19 vaccination. Am. J. Vet. Res. 39:883-886. (Pubitemid 10213526)
16. Ko J, Gendron-Fitzpatrick A, Ficht TA, Splitter GA. 2002. Virulence criteria for Brucella abortus strains as determined by interferon regulatory factor 1-deficient mice. Infect. Immun. 70:7004-7012. (Pubitemid 35387936)
17. Magnani DM, Harms JS, Durward MA, Splitter GA. 2009. Nondividing but metabolically active gamma-irradiated Brucella melitensis is protective against virulent B. melitensis challenge in mice. Infect. Immun. 77:5181-5189.
18. Mallory RM, et al. 2010. Safety and immunogenicity following administration of a live, attenuated monovalent 2009 H1N1 influenza vaccine to children and adults in two randomized controlled trials. PLoS One 5:e13755.
19. McElligott DL, et al. 1997. CD4+ T cells from IRF-1-deficient mice exhibit altered patterns of cytokine expression and cell subset homeostasis. J. Immunol. 159:4180-4186. (Pubitemid 127470572)
20. Nicoletti P. 1990. Vaccination against Brucella. Adv. Biotechnol. Processes 13:147-168.
21. Orme IM. 2006. Preclinical testing of new vaccines for tuberculosis: a comprehensive review. Vaccine 24:2-19. (Pubitemid 41721096)
22. Pappas G, Akritidis N, Bosilkovski M, Tsianos E. 2005. Brucellosis. N. Engl. J. Med. 352:2325-2336.
23. Parent MA, et al. 2007. Brucella abortus bacA mutant induces greater pro-inflammatory cytokines than the wild-type parent strain. Microbes Infect. 9:55-62. (Pubitemid 46149418)
24. Perkins SD, Smither SJ, Atkins HS. 19 January 2010. Towards a Brucella vaccine for humans. FEMS Microbiol. Rev. [Epub ahead of print.]
25. Remick DG. 2007. Pathophysiology of sepsis. Am. J. Pathol. 170:1435-1444. (Pubitemid 47339289)
26. Romagnani S. 2000. T-cell subsets (Th1 versus Th2). Ann. Allergy Asthma Immunol. 85:9-18.
27. Schurig GG, Sriranganathan N, Corbel MJ. 2002. Brucellosis vaccines: past, present and future. Vet. Microbiol. 90:479-496. (Pubitemid 35282500)
28. Seleem MN, Boyle SM, Sriranganathan N. 2010. Brucellosis: a reemerging zoonosis. Vet. Microbiol. 140:392-398.
29. Silva TM, Costa EA, Paixao TA, Tsolis RM, Santos RL. 2011. Laboratory animal models for brucellosis research. J. Biomed. Biotechnol. 2011:518323.
30. Sirard JC, Niedergang F, Kraehenbuhl JP. 1999. Live attenuated Salmonella: a paradigm of mucosal vaccines. Immunol. Rev. 171:5-26. (Pubitemid 29504709)
31. Soothill JS, Morton DB, Ahmad A. 1992. The HID50 (hypothermia-inducing dose 50): an alternative to the LD50 for measurement of bacterial virulence. Int. J. Exp. Pathol. 73:95-98.
32. Sun YH, den Hartigh AB, Santos RL, Adams LG, Tsolis RM. 2002. virB-mediated survival of Brucella abortus in mice and macrophages is independent of a functional inducible nitric oxide synthase or NADPH oxidase in macrophages. Infect. Immun. 70:4826-4832.
33. Taniguchi T, Ogasawara K, Takaoka A, Tanaka N. 2001. IRF family of transcription factors as regulators of host defense. Annu. Rev. Immunol. 19:623-655. (Pubitemid 32368048)
34. Vemulapalli R, et al. 2004. Enhanced efficacy of recombinant Brucella abortus RB51 vaccines against B. melitensis infection in mice. Vet. Microbiol. 102:237-245. (Pubitemid 39144399)
35. Weeks JN, et al. 2010. Brucella melitensis VjbR and C12-HSL regulons: contributions of the N-dodecanoyl homoserine lactone signaling molecule and LuxR homologue VjbR to gene expression. BMC Microbiol. 10:167.
36. Yang X, Thornburg T, Walters N, Pascual DW. 2010. deltaznuAdeltapurE Brucella abortus 2308 mutant as a live vaccine candidate. Vaccine 28:1069-1074.